NHS app to become default source for appointments, screenings and test results
It will also avoid the need for at least 50 million NHS letters being sent by post each year, with the Health Secretary likening the shift from analogue to digital to 'online banking or ordering a takeaway'.
The £50 million investment will see 270 million messages sent through the NHS app this year, an increase of 70 million on the previous financial year.
Push notifications will provide appointment reminders to patients to try to reduce the risk of no attendance, with around eight million missed appointments in elective care missed in 2023/24.
📱 Do you have your NHS App notifications on?
📩 To help patients, over 160 million messages were sent via the NHS App in the last year.
✅ Turn notifications on to get the most out of your NHS App.
Learn more: https://t.co/yLdDutSNa5 pic.twitter.com/BQbnRhv92B
— Department of Health and Social Care (@DHSCgovuk) June 7, 2025
More than 11 million people in the UK currently log into the NHS app every month, while almost 20 million are opted in to receive healthcare messages from the app.
Where app messaging is not available, particularly for elderly patients without smartphones, communications will be sent via text message and then by letter as a last resort and phone lines will be freed up.
It is hoped the changes will give patients better access to manage their healthcare journey and make informed decisions about their care.
NHS app services, which were launched in December 2018, are now used in 87% of hospitals across England.
Last month, NHS England announced millions of patients would be able to get 'Amazon-style' tracking updates on their prescriptions through the app, to check if their medicines are ready to collect or have been despatched for delivery.
Health Secretary Wes Streeting said: 'People are living increasingly busy lives and want to access information about their health at the touch of a button, rather than having to wait weeks for letters that often arrive too late.
'This Government is bringing our analogue health service into the digital age, so that being a patient in the NHS is as convenient as online banking or ordering a takeaway.
'The NHS still spends hundreds of millions of pounds on stamps, printing, and envelopes. By modernising the health service, we can free up huge amounts of funding to reinvest in the front line.
'Through the investment and reform in our Plan for Change, we will make the NHS App the front door to the health service and put power in the hands of patients.'
Rachel Power, chief executive of the Patient's Association, said: 'This major upgrade to the NHS App marks a significant step in modernising how patients receive information, from test results to screening invitations.
'This was a recommendation from our Digital Coalition and realises changes that patients have asked for.
'We welcome this investment and the ambition behind it. Success for any digital innovation will be the implementation of the Digital Inclusion Plan and working directly with patients and communities.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Glasgow Times
2 hours ago
- Glasgow Times
Type 2 diabetes patients set for major shake-up in care
The health service should move from a one-size-fits-all approach of starting everyone on the same medication, to more personalised care that aims to prevent complications like heart failure and heart attacks, according to new draft guidance from the National Institute for Health and Care Excellence (Nice). This includes making newer type 2 diabetes drugs, known as SGLT-2 inhibitors, a first-line treatment option in a move that could eventually help save tens of thousands of lives. SGLT-2 inhibitors, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, are once-a-day tablets that reduce blood sugar levels by helping the kidneys remove glucose, which is passed from the body through urine. However, analysis by Nice found these drugs are under-prescribed. The new guidelines recommend patients who cannot tolerate metformin – the first-choice in type 2 diabetes medication – should start with an SGLT-2 inhibitor on its own. The decision comes after evidence suggested these drugs protect the heart and kidneys as well as controlling blood sugar, Nice said. It is estimated the change could save almost 22,000 lives once uptake reaches 90% of the population. Nice also suggests some groups of patients would also benefit from GLP-1 receptor agonists such as liraglutide or semaglutide sooner, rather than keeping them for the later stages of treatment. Semaglutide, sold under the brand name Ozempic, is licensed in the UK to treat type 2 diabetes, while its other brand – Wegovy – is also used by the NHS to help obese people lose weight. Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice, said: 'This guidance means more people will be offered medicines where it is right to do so to reduce their future risk of ill health. 'This represents a significant evolution in how we approach type 2 diabetes treatment. 'We're moving beyond simply managing blood sugar to taking a holistic view of a person's health, particularly their cardiovascular and kidney health. 'The evidence shows that certain medicines can provide important cardiovascular benefits, and by recommending them as part of initial treatment, we could help prevent heart attacks, strokes and other serious complications before they occur. 'This is particularly important given that cardiovascular disease is the leading cause of death in people with type 2 diabetes.' Around 4.6 million people in the UK are living with diabetes, with nine in 10 of those having type 2. However, it is estimated that a further 1.3 million people may have undiagnosed type 2 diabetes. Nice analysed the records of 590,000 people and found SGLT-2 inhibitors are under-prescribed, particularly to women, older people, and black patients. Prof Benger added: 'The evidence from our analysis is clear. There are prescribing gaps that need to be addressed. 'The guideline update published today will help to increase equitable uptake of SGLT-2 inhibitors, which we know can prevent serious health complications.' Dr Waqaar Shah, chairman of the guideline committee, added: 'We know that SGLT-2 inhibitors are currently under-prescribed, and our health economics analysis shows that people living in the most deprived areas would particularly benefit from universal access to these treatments. 'These recommendations could help reduce health inequalities while providing better outcomes for everyone.' Elsewhere, the draft guidance suggests different treatments for diabetes patients with certain characteristics or health conditions. These include adults with cardiovascular disease, who should be offered a triple therapy including a GLP-1 receptor agonist. Meanwhile, adults diagnosed with type 2 diabetes before 40 should be offered dual therapy before a GLP-1 receptor agonist is considered, while patients with chronic kidney disease should have tailored recommendations based on their kidney function. A public consultation on the new Nice guidelines is open until October 2. Douglas Twenefour, head of clinical at Diabetes UK, said: 'This long-awaited announcement propels type 2 diabetes treatment into the 21st century. 'Boosting access to newer treatments will be transformative for people with type 2 diabetes, while ensuring the UK keeps pace with the global momentum in treating the condition. 'The majority of people with type 2 diabetes are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications. 'Diabetes is a leading cause of cardiovascular disease, and tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease. 'These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes.'
Glasgow Times
2 hours ago
- Glasgow Times
At-home hepatitis C tests identify hundreds with the virus
Officials said more than 100,000 people have ordered at-home hepatitis C tests since the service was launched in May 2023. This includes 15,463 tests ordered in the week after the Infected Blood Inquiry published its final report on May 2024. Hepatitis C often shows no signs until serious damage is done. It can be treated, so testing is key to help you help reduce your risk. #WorldHepatitisDay #HepC🔗 — UK Health Security Agency (@UKHSA) July 28, 2025 Hepatitis C is a virus that is passed on through blood-to-blood contact and infects the liver. The disease is known as a 'silent killer' as some people can live with the virus for many years before realising that they are infected. But the delay in diagnosis can lead to irreparable liver damage, including scarring and cancer. If people test positive they can often be treated by taking antiviral tablets to fight off the virus for several weeks. People who test positive may also be offered a test to see whether any damage has been caused to the liver. Health officials said that 105,998 people have ordered an at-home NHS hepatitis C test online since the service was launched in 2023. Among those diagnosed under the NHS scheme so far, NHS England said that seven in 10 are from deprived communities. And it said that the most common risk factors reported by positive cases include injecting drug use, sharing needles and other drug paraphernalia and a history of prison. It is understood that only a very small number identified after ordering a test online had a positive result after receiving contaminated blood. In May this year NHS England also launched a system which means that people of a certain age who newly register with GP practices in England will be asked if they had a blood transfusion prior to 1996 in a bid to find more victims of the infected blood scandal. The Infected Blood Inquiry, which examined the scandal in depth, recommended that the health service should work to 'find the undiagnosed'. More than 30,000 people in the UK were infected with HIV and hepatitis C after they were given contaminated blood and blood products between the 1970s and early 1990s. And more than 3,000 people have died as a result while survivors are living with lifelong health implications. Professor Meghana Pandit, NHS national medical director, said 'We want to make it easier for people to access care before hidden viruses like hepatitis C cause people serious harm. 'The home testing service is available to everyone, and through targeted outreach to people at higher risk we are helping thousands avoid serious illness and reducing health inequalities in the process. 'If you or someone you know might be at risk, order a free and confidential test today via the NHS hepatitis C testing website – it could save your life.' Sema Mandal, deputy director for blood safety at UK Health Security Agency, said: 'Our data shows that the number of people with hepatitis C in England is continuing to fall, thanks to more people getting tested and taking treatment that clears the virus. 'I'm delighted to hear that 100,000 of the free self-testing kits have already been ordered via NHS online and this should further help us defeat this disease.' Rachel Halford, chief executive of The Hepatitis C Trust, said: 'Reaching 100,000 home tests is an incredible milestone as we push closer towards the elimination of hepatitis C. 'This option of home testing allows people with any concerns to get a free, confidential test without the need to attend a clinic. For many hesitant to access health services, this can act as a lifeline. 'While injecting drug use remains a key risk factor, it is equally important to remember those affected by the infected blood scandal – the most devastating treatment disaster in the history of the NHS. 'If you received a blood transfusion or blood products before 1996, we strongly encourage you to order a test. Even for peace of mind alone, it could be invaluable. Today's treatments are highly effective, simple to take, and come with minimal side effects.'
Rhyl Journal
2 hours ago
- Rhyl Journal
At-home hepatitis C tests identify hundreds with the virus
Officials said more than 100,000 people have ordered at-home hepatitis C tests since the service was launched in May 2023. This includes 15,463 tests ordered in the week after the Infected Blood Inquiry published its final report on May 2024. Hepatitis C often shows no signs until serious damage is done. It can be treated, so testing is key to help you help reduce your risk. #WorldHepatitisDay #HepC🔗 — UK Health Security Agency (@UKHSA) July 28, 2025 Hepatitis C is a virus that is passed on through blood-to-blood contact and infects the liver. The disease is known as a 'silent killer' as some people can live with the virus for many years before realising that they are infected. But the delay in diagnosis can lead to irreparable liver damage, including scarring and cancer. If people test positive they can often be treated by taking antiviral tablets to fight off the virus for several weeks. People who test positive may also be offered a test to see whether any damage has been caused to the liver. Health officials said that 105,998 people have ordered an at-home NHS hepatitis C test online since the service was launched in 2023. Among those diagnosed under the NHS scheme so far, NHS England said that seven in 10 are from deprived communities. And it said that the most common risk factors reported by positive cases include injecting drug use, sharing needles and other drug paraphernalia and a history of prison. It is understood that only a very small number identified after ordering a test online had a positive result after receiving contaminated blood. In May this year NHS England also launched a system which means that people of a certain age who newly register with GP practices in England will be asked if they had a blood transfusion prior to 1996 in a bid to find more victims of the infected blood scandal. The Infected Blood Inquiry, which examined the scandal in depth, recommended that the health service should work to 'find the undiagnosed'. More than 30,000 people in the UK were infected with HIV and hepatitis C after they were given contaminated blood and blood products between the 1970s and early 1990s. And more than 3,000 people have died as a result while survivors are living with lifelong health implications. Professor Meghana Pandit, NHS national medical director, said 'We want to make it easier for people to access care before hidden viruses like hepatitis C cause people serious harm. 'The home testing service is available to everyone, and through targeted outreach to people at higher risk we are helping thousands avoid serious illness and reducing health inequalities in the process. 'If you or someone you know might be at risk, order a free and confidential test today via the NHS hepatitis C testing website – it could save your life.' Sema Mandal, deputy director for blood safety at UK Health Security Agency, said: 'Our data shows that the number of people with hepatitis C in England is continuing to fall, thanks to more people getting tested and taking treatment that clears the virus. 'I'm delighted to hear that 100,000 of the free self-testing kits have already been ordered via NHS online and this should further help us defeat this disease.' Rachel Halford, chief executive of The Hepatitis C Trust, said: 'Reaching 100,000 home tests is an incredible milestone as we push closer towards the elimination of hepatitis C. 'This option of home testing allows people with any concerns to get a free, confidential test without the need to attend a clinic. For many hesitant to access health services, this can act as a lifeline. 'While injecting drug use remains a key risk factor, it is equally important to remember those affected by the infected blood scandal – the most devastating treatment disaster in the history of the NHS. 'If you received a blood transfusion or blood products before 1996, we strongly encourage you to order a test. Even for peace of mind alone, it could be invaluable. Today's treatments are highly effective, simple to take, and come with minimal side effects.'
